Semaglutide 2 mg/vial – US Stock

Semaglutide 2 mg/vial from Hilma Biocare is a glucagon-like peptide-1 receptor agonist (GLP-1 RA) supplied as lyophilized powder. The product contains 2 mg of semaglutide per vial and has a stated active half-life of up to 7 days.

Product Overview

Semaglutide is a GLP-1 receptor agonist that acts on pathways involved in glucose regulation and appetite control. The supplied information identifies semaglutide as a pharmaceutical compound used in the management of type 2 diabetes and, at specific formulations and strengths, for long-term weight management in certain adults.

Its reported pharmacological actions include increasing glucose-dependent insulin secretion, reducing glucagon secretion, slowing gastric emptying, and influencing appetite. These properties contribute to its effects on blood glucose regulation and food intake.

Active Ingredient

The active ingredient is Semaglutide, a glucagon-like peptide-1 receptor agonist.

Form and Strength

The product is supplied as lyophilized powder for injection, with a stated strength of 2 mg per vial.

Product Characteristics

According to the supplied specifications, Semaglutide has the following characteristics:

• GLP-1 receptor agonist
• Peptide hormone
• Lyophilized injectable powder
• 2 mg per vial
• Active half-life of up to 7 days
• One vial per pack
• No water retention listed
• No aromatization listed

Product Specifications

Mechanism of Action

Semaglutide acts as a GLP-1 receptor agonist. GLP-1 is a naturally occurring hormone involved in glucose and appetite regulation.

The supplied information describes several key pharmacological actions:

• Insulin secretion: Semaglutide increases insulin release in response to elevated blood glucose.
• Glucagon regulation: It reduces glucagon secretion, contributing to blood glucose control.
• Gastric emptying: It delays gastric emptying, which can influence the rate at which nutrients enter circulation.
• Appetite regulation: GLP-1 receptor activity can reduce appetite and food intake.

The combined effects make semaglutide relevant to metabolic and weight-management research and clinical applications.

Weight Management and Metabolic Research

The supplied product information describes semaglutide as an anti-obesity medication used for long-term weight management in certain adults with obesity or overweight accompanied by a weight-related comorbidity.

The source also reports effects on body weight, appetite, blood glucose, plasma lipids, systolic blood pressure, and inflammatory markers in clinical research. Individual results can vary, and clinical study outcomes should not be interpreted as guaranteed results for an individual.

Important Safety Information

Semaglutide is a pharmacologically active GLP-1 receptor agonist. The supplied information identifies several medical considerations, including a history of:

• Pancreatitis
• Kidney disease
• Diabetic retinopathy or other diabetes-related eye complications
• Diabetic ketoacidosis

The supplied warnings also state that semaglutide should not be used by individuals with multiple endocrine neoplasia type 2 (MEN 2) or a personal or family history of medullary thyroid carcinoma.

Individuals should discuss their medical history and current medications with a qualified healthcare professional before using semaglutide.

Important Information

This product information is provided for product identification and general informational purposes and does not constitute personalized medical advice.

No dosing recommendations, injection instructions, reconstitution procedures, weight-loss programs, or treatment protocols are provided. The dosing information contained in the source material has intentionally not been converted into usage instructions.

Semaglutide is not intended for people with type 1 diabetes according to the supplied information.

About Hilma Biocare USA

Semaglutide 2 mg/vial is part of the Hilma Biocare product range. The product contains a stated 2 mg quantity of semaglutide and is supplied as one vial of lyophilized injectable powder, listed as US Stock.